The purpose is to test the hypothesis that microdrop instillation of combined phenylephrine 1.67% and tropicamide 0.33% eyedrops causes at least equal mydriasis compared with standard drop instillation of the same mydriatic regimen, which constitutes routine care for pupil dilation during retinopathy of prematurity (ROP) screening in our neonatal intensive care unit. Comparison, also, will be made to the subsequent adverse events and the drug concentration in peripheral blood samples.
A non-inferiority, crossover, randomized controlled trial will be conducted for this purpose. Participants will be randomly assigned to receive either a) microdrops on their first and standard drops on their second screening examination a week later (M/S group), or b) standard drops first and microdrops a week later (S/M group). Microdrops (6.5 μL) will be instilled using a calibrated micropipette, while standard drops (28-34 μL) will be instilled directly through the commercially available plastic multi-dose mydriatic dropper bottle.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SCREENING
Masking
QUADRUPLE
Enrollment
83
1 drop (6.5 μL) for 3 doses with 5-minute intervals
1 drop (28-34 μL) for 3 doses with 5-minute intervals
Papageorgiou General Hospital
Thessaloniki, Greece
Mydriatic efficacy: millimeters of horizontal pupil diameter.
Time frame: 45 minutes after the first drop instillation.
Mydriasis sustainability: millimeters of horizontal pupil diameter.
Time frame: 90 minutes after the first drop instillation.
Mydriasis sustainability: millimeters of horizontal pupil diameter.
Time frame: 120 minutes after the first drop instillation.
Pharmacokinetic profile of phenylephrine: area under the whole blood concentration versus time curve (AUC).
Each participant will be sampled once (random allocation to one time-point). Blood sampling will be combined with peripheral blood collection for routine examinations.
Time frame: Blood sampling at 15, 20, 25, 30, 40, 50, 60, 120, and 180 minutes after the first drop instillation.
Pharmacokinetic profile of phenylephrine: maximum (peak) whole blood concentration (Cmax).
Each participant will be sampled once (random allocation to one time-point). Blood sampling will be combined with peripheral blood collection for routine examinations.
Time frame: Blood sampling at 15, 20, 25, 30, 40, 50, 60, 120, and 180 minutes after the first drop instillation.
Pharmacokinetic profile of phenylephrine: time to reach maximum (peak) whole blood concentration (Tmax).
Each participant will be sampled once (random allocation to one time-point). Blood sampling will be combined with peripheral blood collection for routine examinations.
Time frame: Blood sampling at 15, 20, 25, 30, 40, 50, 60, 120, and 180 minutes after the first drop instillation.
Pharmacokinetic profile of phenylephrine: elimination half-life (T1/2).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Each participant will be sampled once (random allocation to one time-point). Blood sampling will be combined with peripheral blood collection for routine examinations.
Time frame: Blood sampling at 15, 20, 25, 30, 40, 50, 60, 120, and 180 minutes after the first drop instillation.
Heart rate values (beats per minute).
Time frame: 45, 90 and 120 minutes after the first drop instillation.
Oxygen saturation (SpO2) values (%).
Time frame: 45, 90 and 120 minutes after the first drop instillation.
Systolic, diastolic, and mean blood pressure values (mmHg).
Time frame: 45, 90 and 120 minutes after the first drop instillation. Hourly blood pressure measurements for the first 24 hours after mydriasis.
Number of participants with systemic adverse events.
Apnea, increased gastric residuals, inhibited duodenal motor activity, delayed gastric emptying, feeding intolerance, abdominal distension, vomiting, paralytic ileus, acute gastric dilatation, necrotizing enterocolitis (NEC).
Time frame: During the 48 hours after mydriasis.
Number of participants with local adverse events.
Periorbital pallor, eyelid swelling, flushing.
Time frame: 45 minutes after the first drop instillation.
Adequacy of judging the presence or absence of treatment-requiring ROP.
Time frame: At the end of the eye examination (fundoscopy).